FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO)Medical paper search AI "Amanogawa"We are pleased to inform you that Kaken Pharmaceutical Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, President: Hiroyuki Horiuchi, hereinafter Kaken Pharmaceutical Co., Ltd.) has introduced the product.

 

　RIKEN Pharmaceutical has produced a large number of extremely important scientists in the history of Japanese science, including Yoshio Nishina, the father of modern physics, Hideki Yukawa, and Shinichiro Tomonaga, who are Nobel laureates. It was founded in 1948 with its roots.Starting with the manufacture and sale of penicillin in the same year, we develop, manufacture and sell various pharmaceutical products, and our strength is in the therapeutic fields such as dermatology and orthopedics. Amanogawa will be used at the head office and the New Drug Creation Center in Shizuoka, Kyoto.

 

Comment from Mr. Tatsuhiro Harada, Director, New Drug Creation Center, Kaken Pharmaceutical Co., Ltd.
　"By being able to search for information using Amanogawa, which is equipped with FRONTEO's original AI engine, we can obtain the necessary information in an extremely short time, and in addition, we have realized new things that could not be achieved by conventional literature searches. We believe that we will be able to meet information that is connected. By utilizing this information and accelerating drug discovery research, we will provide more excellent medicines than ever before and improve the quality of life of patients. Will contribute to. "

 

　Amanogawa is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)".Enter the word, sentence, hypothesis, etc. you want to look up, and AI will PubMed^*Instantly detect related papers from the data of more than 3000 million papers published in. By utilizing AI, in addition to greatly improving the efficiency of paper search and analysis, which required a huge amount of time for human work, information that could not be found by conventional keyword search and bias by searchers It makes it possible to find information that is not available, and realizes objective and comprehensive analysis in medical and drug discovery research.

 

　FRONTEO will promote research and development so that it can contribute to the development of medical care, medicine, and pharmacy through the provision of AI systems.

 

* PubMed: A database of biomedical papers created by the National Center for Biological Sciences in the National Library of Medicine.

 

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder (Trademark: concept encoder, reading: Concept Encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​that have been accumulated in the life science field.Patent registration number: Patent No. 6346367.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT", "Concept Encoder", and "Looca Cross" specializing in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been developed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.